论文部分内容阅读
藤黄酸(以下简称“736-2”)临床应用,对乳腺癌、宫颈癌、皮肤癌等有一定疗效。灌服“736-2”对小鼠艾氏腹水癌(以下简称E)无明显影响。腹腔注射“736-2”对实体型无效,对其腹水型有一定抑制作用,但不能延长荷瘤动物的寿命。为了进一步分析“736-2”对E的作用,进行了如下实验。实验方法按本实验室抗癌药体内筛选实验常规,以无菌手续取第九天E腹水,用生理盐水稀释一倍,接种0.2毫升于瑞士种雄性小自鼠(体重20-21克)腹腔。24小时后随机分组。对照
The clinical application of gambogic acid (hereinafter referred to as “736-2”) has a certain effect on breast cancer, cervical cancer, and skin cancer. Gavage “736-2” had no significant effect on Ehrlich ascites carcinoma (E). Intraperitoneal injection of “736-2” has no effect on solid type, but it has a certain inhibitory effect on its ascites type, but it can not prolong the life span of tumor-bearing animals. In order to further analyze the effect of “736-2” on E, the following experiment was conducted. Experimental method According to the in-vivo screening experiment of the anticancer drug in the laboratory, the ascitic fluid was taken on the ninth day as E ascites, diluted twice with physiological saline, and inoculated with 0.2 ml of a Swiss male small mouse (weight 20-21 g). . Randomly grouped after 24 hours. Control